Agilent Acquires Biocare Medical for $950 Million

Agilent Acquires Biocare Medical for $950 Million Agilent Technologies announced a significant acquisition of Biocare Medical for $950 million in an all-cash transaction, marking a strategic expansion into the pathology diagnostics market. This deal represents Agilent's commitment to strengthening its presence in the growing field of anatomical pathology and cancer diagnostics. Biocare Medical specializes in developing and commercializing antibodies, reagents, and assay kits used by pathologists and researchers to identify and diagnose various diseases, particularly cancer. The company's portfolio includes innovative immunohistochemistry and immunofluorescence products that are essential tools in modern diagnostic laboratories worldwide.